Blocking Regulatory Immune System Proteins May Help Combat HIV

Temporarily blocking type 1 interferon, combined with the use of antiretroviral therapy (ART), may restore immune function and speed up viral suppression against HIV, according to a study published in the Journal of Clinical Investigation. The study is the first to demonstrate the role type 1 interferon plays in driving the body’s immune destruction during HIV infection, according to the authors.

“This findings is completely counterintuitive, because many believe that the more interferon at work, the better,” said investigator Scott Kitchen. “We show that the type of interferon being produced during chronic stages of HIV infection has detrimental effects on the body’s ability to fight off HIV and other types of infection or cancer, and could actually be contributing to accelerated HIV disease.”

The investigators wanted to block type 1 interferon in order to reduce chronic activation of the immune cells, allowing the exhausted CD8 T cells to restore their abilities to fighting strength.

The investigators used mouse models that had their immune systems replaced with human immune system cells, thymus tissue, and bone marrow. The HIV-infected mice were treated with antibodies that blocked type 1 interferons, so that their immune systems could revert from a state of exhaustion, according to the study.

This process allowed the immune system to produce sufficient amounts of CD8 T cells that sought to attack and kill HIV-infected cells. When combined with ART, the treatment accelerated the effect of ART in suppressing HIV, according to the study.

“We found––counterintuitively––that blocking this immune response against the virus had beneficial effects in lowering the amounts of virus and increasing the ability of the immune response to clear out the virus,” Kitchen said.

The authors noted that although the findings are not definitive, they offer a proof of principle in a humanized mouse system.

“This could have profound implications for the development of therapies that include such approaches as interferon alpha therapy,” said lead investigator Anjie Zhen. “This shows that a proper balance is required when administering this type of therapy, where too much can have detrimental effects in suppressing important immune responses.”

More experiments are needed in non-human primates before moving on to human clinical trials, the authors concluded.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.
By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways.
Diets high in foods such as vegetables, fruit, and healthy fats found to lower the risk of death from all causes, cardiovascular disease, and cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$